| 期刊簡介 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Expert Review of Clinical Immunology LetPub Score 6.3
50 ratings
Rate
Reputation 7.6 Influence 5.1 Speed 7.0 | ||||||||||||||||||||
| 期刊簡稱 | EXPERT REV CLIN IMMU | ||||||||||||||||||||
| ISSN | 1744-666X | ||||||||||||||||||||
| E-ISSN | 1744-8409 | ||||||||||||||||||||
| h-index | 42 | ||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||
| 自引率 (2023-2024) | 0.00%自引率趨勢 | ||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||
| 官方網站 | http://www.tandfonline.com/toc/ierm20/current#.V48dSUz9cSQ | ||||||||||||||||||||
| 在線稿件提交 | https://mc.manuscriptcentral.com/erm | ||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||
| 出版商 | Taylor and Francis Ltd. | ||||||||||||||||||||
| 主題領域 | IMMUNOLOGY | ||||||||||||||||||||
| 出版國/地區 | UNITED STATES | ||||||||||||||||||||
| 發行頻率 | 隔月刊行 | ||||||||||||||||||||
| 創刊年 | 2005 | ||||||||||||||||||||
| 每年文章數 | 133每年文章數趨勢 | ||||||||||||||||||||
| 黃金OA百分比 | 15.07% | ||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q2
| ||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1744-666X%5BISSN%5D | ||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Expert Review of Clinical Immunology] 的評論 | 撰寫評論 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 23:02:20 評論於 The majority of Chinese names are written in pinyin  (0) 讚！ | 维尔娜菲茨杰拉德  |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 22:52:16 評論於 The number of corresponding authors for SCI journal papers is not necessarily limited to one, and there is no fixed standard for how many there can be. This is because different SCI journals have different policies regarding the number of corresponding authors. For SCI journals that only allow one corresponding author, if the paper lists multiple corresponding authors, the first corresponding author will automatically be selected as the corresponding author. For SCI journals that allow two corresponding authors, two corresponding authors can be listed. Other requirements follow the same logic. In other words, the number of corresponding authors listed by the authors must comply with the regulations of the target SCI journal. The first author of an SCI paper is the person who has made the greatest contribution to the experimental work and writing of the paper, and is the person whose name appears first in the author list. However, in cases of multiple authors collaborating, it is common to have joint first authors. There is no specific regulation on the number of joint first authors, as it is greatly related to the workload and length of the paper, as well as the regulations of the publishing journal and institutional recognition. Generally speaking, having 2-4 first authors in an SCI paper is the most common (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 陶宜三岁啦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-27 22:37:27 評論於 How many corresponding authors can there be at most? How many first authors can there be at most? (0) 讚！ | 陶宜三岁啦 |
| 作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-27 08:33:27 評論於 Can the author write their name in Chinese? (0) 讚！ | Oswald Edie |
| 作者: 黑山敏涵 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-06-06 12:49:34 評論於 Review speed: 3.0 | Submission acceptance rate: 25.0 Experience sharing: The speed is average, relatively slow (0) 讚！ | 黑山敏涵 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
